RENOGRAFIN-76 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Renografin-76, and when can generic versions of Renografin-76 launch?
Renografin-76 is a drug marketed by Bracco and is included in one NDA.
The generic ingredient in RENOGRAFIN-76 is diatrizoate meglumine; diatrizoate sodium. There is one drug master file entry for this compound. Four suppliers are listed for this compound. Additional details are available on the diatrizoate meglumine; diatrizoate sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Renografin-76
A generic version of RENOGRAFIN-76 was approved as diatrizoate meglumine; diatrizoate sodium by ADAPTIS on June 27th, 2022.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for RENOGRAFIN-76?
- What are the global sales for RENOGRAFIN-76?
- What is Average Wholesale Price for RENOGRAFIN-76?
Summary for RENOGRAFIN-76
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| DailyMed Link: | RENOGRAFIN-76 at DailyMed |
Pharmacology for RENOGRAFIN-76
| Drug Class | Radiographic Contrast Agent |
| Mechanism of Action | X-Ray Contrast Activity |
US Patents and Regulatory Information for RENOGRAFIN-76
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | RENOGRAFIN-76 | diatrizoate meglumine; diatrizoate sodium | INJECTABLE;INJECTION | 010040-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
